Results of long term iron chelation treatment with deferoxamine

Advances in Experimental Medicine and Biology

Volumn 509, Issue , 2003, Pages 91-125

  Davis, Bernard A ^a   Porter, John B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ASCORBIC ACID; DEFEROXAMINE; DRUG METABOLITE; FERRIMYCIN; FERRIOXAMINE; FERRITIN; HEMOSIDERIN; HYDROXYPYRIDINONE DERIVATIVE; IRON; IRON CHELATE; LIPOXYGENASE; PROCHLORPERAZINE; PYRIDONE DERIVATIVE; SIDEROPHORE; UNCLASSIFIED DRUG; IRON CHELATING AGENT;

ADRENAL INSUFFICIENCY; APHASIA; BACTERIAL INFECTION; BLINDNESS; BONE LESION; COLLAPSE; CONTINUOUS INFUSION; DIABETES MELLITUS; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; ENDOCRINE DISEASE; EYE TOXICITY; GROWTH DISORDER; HEARING LOSS; HEART DISEASE; HEMATOPOIESIS; HEMOCHROMATOSIS; HIGH RISK POPULATION; HUMAN; HYPOPARATHYROIDISM; HYPOTENSION; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYPOTHYROIDISM; IRON BALANCE; IRON CHELATION; IRON OVERLOAD; LIVER FIBROSIS; LONG TERM CARE; LUNG DISEASE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NIGHT BLINDNESS; NONHUMAN; OPTIC NERVE ATROPHY; OTOTOXICITY; OUTCOMES RESEARCH; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RETINOPATHY; REVIEW; SENSORIMOTOR NEUROPATHY; SKIN MANIFESTATION; SURVIVAL RATE; THROMBOCYTOPENIA; TINNITUS; VISUAL FIELD DEFECT; EYE; HISTORY; INNER EAR; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; THALASSEMIA; TIME;

BACTERIA (MICROORGANISMS);

DEFEROXAMINE; EAR, INNER; ENDOCRINE SYSTEM DISEASES; EYE; HEART DISEASES; HISTORY, 20TH CENTURY; HUMANS; INFUSIONS, INTRAVENOUS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; THALASSEMIA; TIME FACTORS;

EID: 0042810743     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (204)

1. Abeysinghe, R.D., Roberts, P.J., Cooper, C.E., MacLean, K.H., Hider, R.C., & Porter, J.B. (1996) The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators. J. Biol. Chem., 271, 7965-7972.
2. Ackrill, P. & Day, J.P. (1985) Desferrioxamine in the treatment of aluminum overload. Clin. Nephrol., 24 Suppl 1, S94-S97.
3. Aldouri, M.A., Wonke, B., Hoffbrand, A.V., Flynn, D.M., Laulicht, M., Fenton, L.A., Scheuer, P.J., Kibbler, C.C., Allwood, C.A., Brown, D., & . (1987) Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. J. Clin. Pathol., 40, 1353-1359.
4. Aldouri, M.A., Wonke, B., Hoffbrand, A.V., Flynn, D.M., Ward, S.E., Agnew, J.E., & Hilson, A.J. (1990) High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol., 84, 113-117.
5. Allain, P., Chaleil, D., Mauras, Y., Beaudeau, G., Varin, M.C., Poignet, J.L., Ciancioni, C., Ang, K.S., Cam, G., & Simon, P. (1987) Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis. Clin. Chim. Acta., 170, 331-338.
6. Anderson, L., Holden, S., Davis, B., Prescott, E., Charrier, C., Bunce, N., Firmin, D., Wonke, B., Porter, J., Walker, J.M., & Pennell, D. (2001). Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. European Heart Journal (in press).
7. Anderson, L., Porter, J.B., Wonke, B., Walker, J.M., Holden, S., Davis, B.A., Prescott, E., Charrier, C., Firmin, D.N., & Pennell, D.J. (2000) Cardiac iron deposition is not predicted by conventional markers of iron overload in homozygous β-thalassaemia. Blood 96, 606a.
8. Angelucci, E., Brittenham, G.M., McLaren, C.E., Ripalti, M., Baronciani, D., Giardini, C., Galimberti, M., Polchi, P., & Lucarelli, G. (2000) Hepatic iron concentration and total body iron stores in thalassemia major. N. Engl. J. Med., 343, 327-331.
9. Angelucci, E., Giovagnoni, A., Valeri, G., Paci, E., Ripalti, M., Muretto, P., McLaren, C., Brittenham, G.M., & Lucarelli, G. (1997) Limitations of magnetic resonance imaging in measurement of hepatic iron. Blood., 90, 4736-4742.
10. Araujo, A., Kosaryan, M., MacDowell, A., Wickens, D., Puri, S., Wonke, B., & Hoffbrand, A.V. (1996) A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload. Br. J. Haematol., 93, 835-837.
11. Arden, G.B., Wonke, B., Kennedy, C., & Huehns, E.R. (1984) Ocular changes in patients undergoing long-term desferrioxamine treatment. Br. J. Ophthalmol., 68, 873-877.
12. Bailey-Wood, R., White, G.P., & Jacobs, A. (1975) The use of Chang cells cultured in vitro for the investigation of cellular iron metabolism. Br. J. Exp. Pathol., 56, 358-362.
13. Bannerman, R.M., Callender, S.T., & Williams, D.L. Effect of desferrioxamine and D.T.P.A. in iron overload. Br. Med. J., 2, 1573-1577. 1962.
14. Barry, M., Flynn, D.M., Letsky, E.A., & Risdon, R.A. (1974) Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. Br. Med. J., 2, 16-20.
15. Baynes, R., Bezwoda, W., Bothwell, T., Khan, Q., & Mansoor, N. (1986) The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein. Scand. J. Clin. Lab Invest., 46, 695-704.
16. Berdoukas, V. (2001) The use of portacaths in patients with transfusion dependent anaemia. The Sydney Children's Hospital experience. S.O.S.T.E. Notiziario 2, 139.
17. Bergeron, C. & Kovacs, K. (1978) Pituitary siderosis. A histologic, immunocytologic, and ultrastructural study. Am. J. Pathol., 93, 295-309.
18. Berkovitch, M., Bistritzer, T., Milone, S.D., Perlman, K., Kucharczyk, W., & Olivieri, N.F. (2000) Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function. J. Pediatr. Endocrinol. Metab., 13, 179-184.
19. Blake, D.R., Winyard, P., Lunec, J., Williams, A., Good, P.A., Crewes, S.J., Gutteridge, J.M., Rowley, D., Halliwell, B., Cornish, A., & . (1985) Cerebral and ocular toxicity induced by desferrioxamine. Q. J. Med., 56, 345-355.
20. Boelaert, J.R., Fenves, A.Z., & Coburn, J.W. (1991) Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am. J. Kidney Dis., 18, 660-667.
21. Borgna-Pignatti, C., De Stefano, P., & Broglia, A.M. (1984) Visual loss in patient on high-dose subcutaneous desferrioxamine. Lancet., 1, 681.
22. Borgna-Pignatti, C., Rugolotto, S., De Stefano, P., Piga, A., Di Gregorio, F., Gamberini, M.R., Sabato, V., Melevendi, C., Cappellini, M.D., & Verlato, G. (1998) Survival and disease complications in thalassemia major. Ann. N.Y. Acad. Sci., 850, 227-231.
23. Borow, K.M., Propper, R., Bierman, F.Z., Grady, S., & Inati, A. (1982) The left ventricular end-systolic pressure-dimension relation in patients with thalassemia major. A new noninvasive method for assessing contractile state. Circulation., 66, 980-985.
24. Bournerias, F., Monnier, N., Dufier, J.L., & Reveillaud, R.J. (1987) [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient]. Nephrologie., 8, 27-29.
25. Bousquet, J., Navarro, M., Robert, G., Aye, P., & Michel, F.B. (1983) Rapid desensitisation for desferrioxamine anaphylactoid reaction. Lancet., 2, 859-860.
26. Boyce, N., Wood, C., Holdsworth, S., Thomson, N.M., & Atkins, R.C. (1985) Life-threatening sepsis complicating heavy metal chelation therapy with desferrioxamine. Aust. N.Z.J. Med., 15, 654-655.
27. Brabec, V., Cermak, J., & Sebestik, V. (1990) Serum ferritin in patients with various haemolytic disorders. Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch., 117, 219-227.
28. Breuer, W., Epsztejn, S., Millgram, P., & Cabantchik, I.Z. (1995) Transport of iron and other transition metals into cells as revealed by a fluorescent probe. Am. J. Physiol., 268, C1354-C1361.
29. Brill, P.W., Winchester, P., Giardina, P.J., & Cunningham-Rundles, S. (1991) Deferoxamine-induced bone dysplasia in patients with thalassemia major. AJR Am. J. Roentgenol., 156, 561-565.
30. Brittenham, G.M., Farrell, D.E., Harris, J.W., Feldman, E.S., Danish, E.H., Muir, W.A., Tripp, J.H., & Bellon, E.M. (1982) Magnetic- susceptibility measurement of human iron stores. N. Engl. J. Med., 307, 1671-1675.
31. Brittenham, G.M., Griffith, P.M., Nienhuis, A.W., McLaren, C.E., Young, N.S., Tucker, E.E., Allen, C.J., Farrell, D.E., & Harris, J.W. (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N. Engl. J. Med., 331, 567-573.
32. Bronspiegel-Weintrob, N., Olivieri, N.F., Tyler, B., Andrews, D.F., Freedman, M.H., & Holland, F.J. (1990) Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N. Engl. J. Med., 323, 713-719.
33. Butzler, J.P., Alexander, M., Segers, A., Cremer, N., & Blum, D. (1978) Enteritis, abscess, and septicemia due to Yersinia enterocolitica in a child with thalassemia. J. Pediatr., 93, 619-621.
34. Canale, V.C., Steinherz, P., New, M., & Erlandson, M. (1974) Endocrine function in thalassemia major. Ann. N.Y. Acad. Sci., 232, 333-345.
35. Caruso-Nicoletti, M., De,S., V, Capra, M., Cardinale, G., Cuccia, L., Di Gregorio, F., Filosa, A., Galati, M.C., Lauriola, A., Malizia, R., Mangiagli, A., Massolo, F., Mastrangelo, C., Meo, A., Messina, M.F., Ponzi, G., Raiola, G., Ruggiero, L., Tamborino, G., & Saviano, A. (1998) Short stature and body proportion in thalassaemia. J. Pediatr. Endocrinol. Metab, 11 Suppl 3, 811-816.
36. Chapman, R.W., Hussain, M.A., Gorman, A., Laulicht, M., Politis, D., Flynn, D.M., Sherlock, S., & Hoffbrand, A.V. (1982) Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload. J. Clin. Pathol., 35, 487-491.
37. Chatterjee, R., Katz, M., Cox, T.F., & Porter, J.B. (1993) Prospective study of the hypothalamic-pituitary axis in thalassaemic patients who developed secondary amenorrhoea. Clin. Endocrinol. (Oxf), 39, 287-296.
38. Chatterjee, R., Katz, M., Oatridge, A., Bydder, G.M., & Porter, J.B. (1998) Selective loss of anterior pituitary volume with severe pituitary-gonadal insufficiency in poorly compliant male thalassemic patients with pubertal arrest. Ann. N.Y. Acad. Sci., 850, 479-482.
39. Chiu, H.Y., Flynn, D.M., Hoffbrand, A.V., & Politis, D. (1986) Infection with Yersinia enterocolitica in patients with iron overload. Br. Med. J. (Clin. Res. Ed), 292, 97.
40. Cohen, A., Martin, M., & Schwartz, E. (1981) Response to long-term deferoxamine therapy in thalassemia. J. Pediatr., 99, 689-694.
41. Cohen, A., Martin, M., & Schwartz, E. (1984) Depletion of excessive liver iron stores with desferrioxamine. Br. J. Haematol., 58, 369-373.
42. Cohen, A.R., Martin, M., & Schwartz, E. (1990) Current treatment of Cooley's anemia. Intravenous chelation therapy. Ann. N.Y. Acad. Sci., 612, 286-291
43. Cohen, A.R., Mizanin, J., & Schwartz, E. (1989) Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. J. Pediatr., 115, 151-155.
44. Cooper, C.E., Lynagh, G.R., Hoyes, K.P., Hider, R.C., Cammack, R., & Porter, J.B. (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem., 271, 20291-20299.
45. Cooper, P.J., Iancu, T.C., Ward, R.J., Guttridge, K.M., & Peters,T.J. (1988) Quantitative analysis of immunogold labelling for ferritin in liver from control and iron-overloaded rats. Histochem. J., 20, 499-509.
46. Costin, G., Kogut, M.D., Hyman, C.B., & Ortega, J.A. (1979) Endocrine abnormalities in thalassemia major. Am. J. Dis. Child., 133, 497-502.
47. Crichton, R.R., Roman, F., & Roland, F. (1980) Iron mobilization from ferritin by chelating agents. J. Inorg. Biochem., 13, 305-316.
48. Cumming, R.L., Millar, J.A., Smith, J.A., & Goldberg, A (1969) Clinical and laboratory studies on the action of desferrioxamine. Br. J. Haematol., 17, 257-263.
49. Davies, S.C., Marcus, R.E., Hungerford, J.L., Miller, M.H., Arden, G.B., & Huehns, E.R. (1983) Ocular toxicity of high-dose intravenous desferrioxamine. Lancet., 2, 181-184.
50. Davis, B.A., O'Sullivan, C., & Porter, J.B. (2001a) Survival in β-thalassaemia major is enhanced by specialist management. Submitted.
51. Davis, B.A., O'Sullivan, C., & Porter, J.B. (2001b) Value of LVEF monitoring in the long-term management of β-thalassaemia. Submitted.
52. Davis, B.A. & Porter, J.B. (2000) Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood., 95, 1229-1236.
53. De Virgiliis, S., Congia, M., Turco, M.P., Frau, F., Dessi, C., Argiolu, F., Sorcinelli, R., Sitzia, A., & Cao, A. (1988) Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch. Dis. Child., 63, 250-255.
54. De Sanctis., V., Stea, S., Savarino, L., Granchi, D., Visentin, M., Sprocati, M., Govoni, R., & Pizzoferrato, A. (2000) Osteochondrodystrophic lesions in chelated thalassemic patients: an histological analysis. Calcif. Tissue Int., 67, 134-140.
55. De Sanctis., V., Stea, S., Savarino, L., Scialpi, V., Traina, G.C., Chiarelli, G.M., Sprocati, M., Govoni, R., Pezzoli, D., Gamberini, R., & Rigolin, F. (1998) Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine. J. Pediatr. Endocrinol. Metab., 11 Suppl 3, 827-833.
56. De Sanctis, V., Vullo, C., Bagni, B., & Chiccoli, L. (1992) Hypoparathyroidism in beta-thalassemia major. Clinical and laboratory observations in 24 patients. Acta Haematol., 88, 105-108.
57. De Sanctis, V., Vullo, C., Katz, M., Wonke, B., Tanas, R., & Bagni, B. (1988a) Gonadal function in patients with beta thalassaemia major. J.Clin. Pathol., 41, 133-137.
58. De Sanctis, V., Zurlo, M.G., Senesi, E., Boffa, C., Cavallo, L., & Di Gregorio, F. (1988b) Insulin dependent diabetes in thalassaemia. Arch. Dis. Child., 63, 58-62.
59. Di Palma, A., Moratelli, S., Tolomelli, P., Giuberti, M., Tenan, R., Fagioli, F., Landi, L., Toffoli, C, Atti, G., & Vullo, C. (1994) Pattern of iron excretion in relation to haemoglobin level and iron load in 8 haematological patients following the administration of subcutaneous deferrioxamine. Eur. J. Haematol., 53, 197-200.
60. Dickerhoff, R. (1987) Acute aphasia and loss of vision with desferrioxamine overdose. Am. J. Pediatr. Hematol. Oncol., 9, 287-288.
61. Drysdale, J.W. & Munro, H.N. (1966) Regulation of synthesis and turnover of ferritin in rat liver. J. Biol. Chem., 241, 3630-3637.
62. Duke-Elder, S. (1969) Diseases of the Lens and Vitreous. St. Louis, CV Mosby.
63. Ehlers, K.H., Giardina, P.J., Lesser, M.L., Engle, M.A., & Hilgartner, M.W. (1991) Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J. Pediatr., 118, 540-545.
64. Engle, M.A., Erlandson, M., & Smith, C.H. (1964) Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 30, 698-705.
65. Epsztejn, S., Kakhlon, O., Glickstein, H., Breuer, W., & Cabantchik, I. (1997) Fluorescence analysis of the labile iron pool of mammalian cells. Anal. Biochem., 248, 31-40.
66. Fischer, R. (2001) SQUID biomagnetic liver susceptometry in the adjustment of chelation treatment. S.O.S.T.E. Notiziario 2, 50-54.
67. Flynn, D.M., Fairney, A., Jackson, D., & Clayton, B.E. (1976) Hormonal changes in thalassaemia major. Arch. Dis. Child., 51, 828-836.
68. Flynn, D.M., Hoffbrand, A.V., & Politis, D. (1982) Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography. Birth Defects Orig. Artic. Ser., 18, 347-353.
69. Fosburg, M.T. & Nathan, D.G. (1990) Treatment of Cooley's anemia. Blood., 76, 435-444.
70. Freedman, M.H., Grisaru, D., Olivieri, N., MacLusky, I., & Thorner, P.S. (1990) Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. Am. J. Dis. Child., 144, 565-569.
71. Freeman, A.P., Giles, R.W., Berdoukas, V.A., Talley, P.A., & Murray, I.P. (1989) Sustained normalization of cardiac function by chelation therapy in thalassaemia major. Clin. Lab Haematol., 11, 299-307.
72. Freeman, A.P., Giles, R.W., Berdoukas, V.A., Walsh, W.F., Choy, D., & Murray, P.C. (1983) Early left ventricular dysfunction and chelation therapy in thalassemia major. Ann. Intern. Med., 99, 450-454.
73. Gabutti, V. & Piga, A. (1996) Results of long-term iron-chelating therapy. Acta Haematol., 95, 26-36.
74. Gallant, T., Freedman, M.H., Vellend, H., & Francombe, W.H. (1986) Yersinia sepsis in patients with iron overload treated with deferoxamine. N. Engl. J. Med., 314, 1643.
75. Gamberini, M.R., Fortini, M., Gilli, G., Testa, M.R., & De, S., V. (1998) Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients. J. Pediatr. Endocrinol. Metab., 11 Suppl 3, 867-869.
76. Gaziev, D., Baronciani, D., Galimberti, M., Polchi, P., Angelucci, E., Giardini, C., Muretto, P., Perugini, S., Riggio, S., Ghirlanda, S., Erer, B., Maiello, A., & Lucarelli, G. (1996) Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature. Bone Marrow Transplant., 17, 409-414.
77. Gelmi, C., Borgna-Pignatti, C., Franchin, S., Tacchini, M., & Trimarchi, F. (1988) Electroretinographic and visual-evoked potential abnormalities in patients with beta-thalassemia major. Ophthalmologica, 196, 29-34.
78. Gertner, J.M., Broadus, A.E., Anast, C.S., Grey, M., Pearson, H., & Genel, M. (1979) Impaired parathyroid response to induced hypocalcemia in thalassemia major. J. Pediatr., 95, 210-213.
79. Giardina, P.J., Ehlers, K.H., Engle, M.A., Grady, R.W., & Hilgartner, M.W. (1985) The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study. Ann. N.Y. Acad. Sci., 445, 282-292.
80. Giardina, P.J., Ehlers, K.H., Grady, R.W., Lesser, M.L., New, M.I., Hilgartner, M.W. (1996) Progress in the management of thalassemia: over a decade and a half of experience with subcutaneous desferrioxamine. Bone Marrow Transplant. 19 Suppl 2, 9-10.
81. Grady, R.W., Giardina, P.J., & Hilgartner, M.W. (1987) Intravenous desferrioxamine and total iron balance. Blood 70, 47a.
82. Graziano, J.H., Markenson, A., Miller, D.R., Chang, H., Bestak, M., Meyers, P., Pisciotto, P., & Rifkind, A. (1978) Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine. J. Pediatr., 92, 648-652.
83. Grundy, R.G., Woods, K.A, Savage, M.O., & Evans, J.P. (1994) Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major. Arch. Dis. Child., 71, 128-132.
84. Guerin, A., London, G., Marchais, S., Metivier, F., & Pelisse, J.M. (1985) Acute deafness and desferrioxamine. Lancet, 2, 39-40.
85. Hartkamp, M.J., Babyn, P.S., & Olivieri, F. (1993) Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients. Pediatr. Radiol., 23, 525-528.
86. Hatori, M., Sparkman, J., Teixeira, C.C., Grynpas, M., Nervina, J., Olivieri, N., & Shapiro, I.M. (1995) Effects of deferoximine on chondrocyte alkaline phosphatase activity: proxidant role of deferoximine in thalassemia. Calcif. Tissue Int., 57, 229-236.
87. Henry, W. Echocardiographic evaluation of the heart in thalassemia major. (1979) In Nienhuis A.W.; moderator. Thalassemia major: molecular and clinical aspects. Ann. Intern. Med. 91, 892-894.
88. Henry, W.L., Nienhuis, A.W., Wiener, M., Miller, D.R., Canale, V.C., & Piomelli, S. (1978) Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition. Am. J. Med., 64, 547-555.
89. Herington, A.C., Werther, G.A., Matthews, R.N., & Burger, H.G. (1981) Studies on the possible mechanism for deficiency of nonsuppressible insulin-like activity in thalassemia major. J. Clin. Endocrinol. Metab., 52, 393-398.
90. Hershko, C., Cook, J.D., & Finch, D.A., (1973) Storage iron kinetics. 3. Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells. J. Lab Clin. Med., 81, 876-886.
91. Hershko, C., Grady, R.W., & Cerami, A. (1978) Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization. J. Lab Clin. Med., 92, 144-151.
92. Hershko, C. & Hoffbrand, A.V. (2000) Iron chelation therapy. Rev. Clin. Exp. Hematol., 4, 337-361.
93. Hershko, C. & Rachmilewitz, E.A. (1979) Mechanism of desferrioxamine-induced iron excretion in thalassaemia. Br. J. Haematol., 42, 125-132.
94. Hoffbrand, A.V., Gorman, A., Laulicht, M., Garidi, M., Economidou, J., Georgipoulou, P., Hussain, M.A., & Flynn, D.M. (1979) Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine. Lancet., 1, 947-949.
95. Hoyes, K.P. & Porter, J.B. (1993) Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br. J. Haematol., 85, 393-400.
96. Hussain, M.A., Green, N., Flynn, D.M., & Hoffbrand, A.V. (1977) Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. Lancet, 1, 977-979.
97. Hussain, M.A., Green, N., Flynn, D.M., Hussein, S., & Hoffbrand, A.V. (1976) Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet, 2, 1278-1280.
98. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. (1995) Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin. Endocrinol. (Oxf), 42, 581-586.
99. Janka, G.E., Mohring, P., Helmig, M., Haas, R.J., & Betke, K. (1981) Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload. Eur. J. Pediatr., 137, 285-290.
100. Jensen, C.E., Tuck, S.M., Old, J., Morris, R.W., Yardumian, A., De Sanctis, V., Hoffbrand, A.V., & Wonke, B. (1997) Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia. Eur. J. Haematol., 59, 76-81.
101. Jensen, C.E., Tuck, S.M., & Wonke, B. (1995) Fertility in beta thalassaemia major: a report of 16 pregnancies, preconceptual evaluation and a review of the literature. Br. J. Obstet. Gynaecol., 102, 625-629.
102. Jensen, P.D., Heickendorff, L., Pedersen, B., Bendix-Hansen, K., Jensen, F.T., Christensen, T., Boesen, A.M., & Ellegaard, J. (1996) The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br. J. Haematol., 94, 288-299.
103. Jensen, P.D., Jensen, F.T., Christensen, T., & Ellegaard, J. (1995) Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients. Br. J. Haematol., 89, 880-889.
104. Keberle, H. (1964) The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. N.Y. Acad. Sci. 119, 758-768.
105. Keberle, H. (1992) From antibiotic to chelating agent In Gross, K., Aumiller, J., Gelzer, J. (eds) Desferrioxamine ®Desferal: History, Clinical Value, Perspectives. Munich, MMV Medizin Verlag, 26-36.
106. Kelly, D.A., Price, E., Jani, B., Wright, V., Rossiter, M., & Walker-Smith, J.A. (1987) Yersinia enterocolitis in iron overload. J. Pediatr. Gastroenterol. Nutr., 6, 643-645.
107. Kletzky, O.A., Costin, G., Marrs, R.P., Bernstein, G., March, C.M., & Mishell, D.R., Jr. (1979b) Gonadotropin insufficiency in patients with thalassemia major. J. Clin. Endocrinol. Metab., 48, 901-905.
108. Konijn, A.M., Glickstein, H., Vaisman, B., Meyron-Holtz, E.G., Slotki, I.N., & Cabantchik, Z.I. (1999) The cellular labile iron pool and intracellular ferritin in K562 cells. Blood., 94, 2128-2134.
109. Koren, G., Bentur, Y., Strong, D., Harvey, E., Klein, J., Baumal, R., Spielberg, S.P., & Freedman, M.H. (1989) Acute changes in renal function associated with deferoxamine therapy. Am. J. Dis. Child., 143, 1077-1080.
110. Kouides, P.A., Slapak, C.A., Rosenwasser, L.J., & Miller, K.B. (1988) Pneumocystis carinii pneumonia as a complication of desferrioxamine therapy. Br. J. Haematol., 70, 383-384.
111. Landau, H., Matoth, I., Landau-Cordova, Z., Goldfarb, A, Rachmilewitz, E.A., & Glaser, B. (1993) Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassaemia major. Clin. Endocrinol. (Oxf), 38, 55-61.
112. Lassman, M.N., O'Brien, R.T., Pearson, H.A., Wise, J.K., Donabedian, R.K., Felig, P., & Genel, M. (1974) Endocrine evaluation in thalassemia major. Ann. N.Y. Acad. Sci., 232, 226-237.
113. Laub, R., Schneider, Y.J., Octave, J.N., Trouet, A., & Crichton, R.R. (1985) Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilization. Biochem. Pharmacol., 34, 1175-1183.
114. Lee, P., Mohammed, N., Marshall, L., Abeysinghe, R.D., Hider, R.C., Porter, J.B., & Singh, S. (1993) Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos., 21, 640-644.
115. Leger, J., Girot, R., Crosnier, H., Postel-Vinay, M.C., & Rappaport, R. (1989) Normal growth hormone (GH) response to GH-releasing hormone in children with thalassemia major before puberty: a possible age-related effect. J. Clin. Endocrinol. Metab., 69, 453-456.
116. Leon, M.B., Borer, J.S., Bacharach, S.L., Green, M.V., Benz, E.J., Jr., Griffith, P., & Nienhuis, A.W. (1979) Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. N. Engl. J. Med., 301, 1143-1148.
117. Levine, J.E., Cohen, A., MacQueen, M., Martin, M., & Giardina, P.J. (1997) Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment. J. Pediatr. Hematol. Oncol., 19, 139-141.
118. Lynch, S.R., Seftel, H.C., Torrance, J.D., Charlton, R.W., & Bothwell, T.H. (1967) Accelerated oxidative catabolism of ascorbic acid in siderotic Bantu. Am. J. Clin. Nutr., 20, 641-647.
119. MacLean, K.H., Cleveland, J.L., & Porter, J.B. (2001) Cellular zinc content is a major determinant of iron-chelator induced apoptosis of thymocytes. Blood (in press).
120. Magro, S., Puzzonia, P., Consarino, C., Galati, M.C., Morgione, S., Porcelli, D., Grimaldi, S., Tancre, D., Arcuri, V., De, S., V., & . (1990) Hypothyroidism in patients with thalassemia syndromes. Acta Haematol., 84, 72-76.
121. Marcus, R.E., Davies, S.C., Bantock, H.M., Underwood, S.R., Walton, S., & Huehns, E.R. (1984) Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major. Lancet, 1, 392-393.
122. Marsh, M.N., Holbrook, I.B., Clark, C., & Shaffer, J.L. (1981) Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine. Postgrad. Med. J., 57, 582-584.
123. Masala, A., Meloni, T., Gallisai, D., Alagna, S., Rovasio, P.P., Rassu, S., & Milia, A.F. (1984) Endocrine functioning in multitransfused prepubertal patients with homozygous beta-thalassemia. J. Clin. Endocrinol. Metab., 58, 667-670.
124. Mavrogeni, S.I., Maris, T., Gouliamos, A., Vlahos, L., & Kremastinos, D.T. (1998) Myocardial iron deposition in beta-thalassemia studied by magnetic resonance imaging. Int. J. Card Imaging, 14, 117-122.
125. McIntosh, N. (1976) Endocrinopathy in thalassaemia major. Arch. Dis. Child., 51, 195-201.
126. Melby, K., Slordahl, S., Gutteberg, T.J., & Nordbo, S.A. (1982) Septicaemia due to Yersinia enterocolitica after oral overdoses of iron. Br. Med. J. (Clin. Res. Ed), 285, 467-468.
127. Merali, S., Chin, K., Del Angel, L., Grady, R.W., Armstrong, M., & Clarkson, A.B., Jr. (1995) Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother., 39, 2023-2026.
128. Merali, S., Chin, K., Grady, R.W., & Clarkson, A.B., Jr. (1996) Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations. Antimicrob. Agents Chemother., 40, 1298-1300.
129. Miller, K.B., Rosenwasser, L.J., Bessette, J.A., Beer, D.J., & Rocklin, R.E. (1981) Rapid desensitisation for desferrioxamine anaphylactic reaction. Lancet., 1, 1059.
130. Modell, B. (1979) Advances in the use of iron-chelating agents for the treatment of iron overload. Prog. Hematol., 11, 267-312.
131. Modell, B. & Berdoukas, V. (1984) Clinical Approach to Thalassaemia. London, Grune and Stratton.
132. Modell, B., Khan, M., & Darlison, M. (2000) Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet, 355, 2051-2052.
133. Modell, B., Letsky, E.A., Flynn, D.M., Peto, R., & Weatherall, D.J. (1982) Survival and desferrioxamine in thalassaemia major. Br. Med. J. (Clin. Res. Ed), 284, 1081-1084.
134. Modell, C.B. & Beck, J. (1974) Long-term desferrioxamine therapy in thalassemia. Ann. N.Y. Acad. Sci., 232, 201-210.
135. Nielsen, P., Fischer, R., Engelhardt, R., Tondury, P., Gabbe, E.E., & Janka, G.E. (1995) Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. Br. J. Haematol., 91, 827-833.
136. Nienhuis, A.W. (1981) Vitamin C and iron. N. Engl. J. Med., 304, 170-171.
137. Nienhuis, A.W., Delea, C., Aamodt, R., Bartter, F., & Anderson, W.F. (1976) Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload. Birth Defects Orig. Artic. Ser., 12, 177-185.
138. O'Brien, R.T. (1974) Ascorbic acid enhancement of desferrioxamine- induced urinary iron excretion in thalassemia major. Ann. N.Y. Acad. Sci., 232, 221-225.
139. Olivieri, N.F., Basran, R.K., Talbot, A.L., Babyn, P., & Bailey, J.D. (1995) Abnormal growth in thalassemia major associated with deferoxamine-induced destruction of spinal cartilage and compromise of sitting height. Blood 86, 482a.
140. Olivieri, N.F., Berriman, A.M., Tyler, B.J., Davis, S.A., Francombe, W.H., & Liu, P.P. (1992a) Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine. Am. J. Hematol., 41, 61-63.
141. Olivieri, N.F. & Brittenham, G.M. (1997) Iron-chelating therapy and the treatment of thalassemia. Blood., 89, 739-761.
142. Olivieri, N.F., Buncic, J.R., Chew, E., Gallant, T., Harrison, R.V., Keenan, N., Logan, W., Mitchell, D., Ricci, G., Skarf, B., & . (1986) Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N. Engl. J. Med., 314, 869-873.
143. Olivieri, N.F., Koren, G., Harris, J., Khattak, S., Freedman, M.H., Templeton, D.M., Bailey, J.D., & Reilly, B.J. (1992b) Growth failure and bony changes induced by deferoxamine. Am. J. Pediatr. Hematol. Oncol., 14, 48-56.
144. Olivieri, N.F., Nathan, D.G., MacMillan, J.H., Wayne, A.S., Liu, P.P., McGee, A., Martin, M., Koren, G., & Cohen, A.R. (1994) Survival in medically treated patients with homozygous beta-thalassemia. N. Engl. J. Med., 331, 574-578.
145. Orzincolo, C., Castaldi, G., De, S., V., Scutellari, P.N., Ciaccio, C., & Vullo, C. (1990) [Rickets-and/or scurvy-like bone lesions in beta-thalassemia major]. Radiol. Med. (Torino), 80, 823-829.
146. Orzincolo, C., Castaldi, G., & Scutellari, P.N. (1994) Platyspondyly in treated beta-thalassemia. Eur. J. Radiol., 18, 129-133.
147. Pall, H., Blake, D.R., Good, P.A., Winyard, P., & Williams, A.C. (1986) Copper chelation and the neuro-ophthalmic toxicity of desferrioxamine. Lancet., 2, 1279.
148. Pengloan, J., Dantal, J., Rossazza, C., Abazza, M., & Nivet, H. (1987) Ocular toxicity after a single intravenous dose of desferrioxamine in 2 hemodialyzed patients. Nephron., 46, 211-212.
149. Perry, R.D. & Brubaker, R.R. (1979) Accumulation of iron by yersiniae. J. Bacteriol., 137, 1290-1298.
150. Piga, A., Longo, F., Consolati, A., Sachetti, L., De Leo, A., Caramellino, L. (1996) Mortality and morbidity in thalassemia with conventional treatment. Bone Marrow Transplant. 19 Suppl 2, 11-13.
151. Piga, A., Luzzatto, L., Capalbo, P., Gambotto, S., Tricta, F., & Gabutti, V. (1988) High-dose desferrioxamine as a cause of growth failure in thalassemic patients. Eur. J. Haematol., 40, 380-381.
152. Piga. A., Muroni, P., Buffardi, S., Magnano, C., Durken, M., Nangeroni, M., Forni, G.L., Pizzarelli, G., Galanello, R., & Longo, F. (2001) Long-term central venous catheter complications during intensive chelation therapy in β-thalassemia patients: a multicenter study. S.O.S.T.E. Notiziario 2, 141.
153. Pintor, C., Cella, S.G., Manso, P., Corda, R., Dessi, C., Locatelli, V., & Muller, E.E. (1986) Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major. J. Clin. Endocrinol. Metab., 62, 263-267.
154. Pippard, M.J., Callender, S.T., & Finch, C.A. (1982a) Ferrioxamine excretion in iron-loaded man. Blood., 60, 288-294.
155. Pippard, M.J., Callender, S.T., & Weatherall, D.J. (1978b) Intensive iron-chelation therapy with desferrioxamine in iron-loading anaemias. Clin. Sci. Mol. Med., 54, 99-106.
156. Pippard, M.J., Johnson, D.K., & Finch, C.A. (1982b) Hepatocyte iron kinetics in the rat explored with an iron chelator. Br. J. Haematol., 52, 211-224.
157. Pippard, M.J., Letsky, E.A., Callender, S.T., & Weatherall, D.J. (1978a) Prevention of iron loading in transfusion-dependent thalassaemia. Lancet, 1, 1178-1181.
158. Polson, R.J., Jawed, A., Bomford, A., Berry, H., & Williams, R. (1985) Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects. Br. Med. J. (Clin. Res. Ed), 291, 448.
159. Porter, J.B., Alberti, A., Hassan, I., Howes, C., Stallibrass, L., Racine, A., Alexander, E., Davis, B., Voi, V., Brookman, L., & Piga, A. (1997) Subcutaneous depot desferrioxamine (CGH 749B); Relationship of pharmacokinetics to efficacy and drug metabolism. Blood 90, 265a.
160. Porter, J.B., Faherty, A., Stallibrass, L., Brookman, L., Hassan, I., & Howes, C. (1998b) A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity. Ann. N.Y. Acad. Sci., 850, 483-487.
161. Porter, J.B., Huehns, E.R., & Hider, R.C. (1989b) The development of iron chelating drugs. Baillieres Clin. Haematol., 2, 257-292.
162. Porter, J.B., Jaswon, M.S., Huehns, E.R., East, C.A., & Hazell, J.W. (1989a) Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br. J. Haematol., 73, 403-409.
163. Porter, J., Singh, S., Mohammed, N., Abeysinghe, R., & Hider, R. (1992) Osteopaenia in thalassaemia major: The relevance of desferrioxamine (DFO) metabolism International Society of Haematology, 24th Congress, London, 47.
164. Porter, J.B., Weir, D.T., Davis, B., Alexander, E., McCombie, R.R., Walker, S.M., Osborne, S., & Lowe, P.J. (1998a) Iron balance and chelation efficiency following single dose depot desferrioxamine. Blood 92, 325a.
165. Propper, R.D., Cooper, B., Rufo, R.R., Nienhuis, A.W., Anderson, W.F., Bunn, H.F., Rosenthal, A., & Nathan, D.G. (1977) Continuous subcutaenous administration of deferoxamine in patients with iron overload. N. Engl. J. Med., 297, 418-423.
166. Propper, R.D., Shurin, S.B., & Nathan, D.G. (1976) Reassessment of the use of desferrioxamine B in iron overload. N. Engl. J. Med., 294, 1421-1423.
167. Rahi, A.H., Hungerford, J.L., & Ahmed, A.I. (1986) Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Br. J. Ophthalmol., 70, 373-381.
168. Rahko, P.S., Salerni, R., & Uretsky, B.F. (1986) Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J. Am. Coll. Cardiol., 8, 436-440.
169. Richardson, M.E., Matthews, R.N., Alison, J.F., Menahem, S., Mitvalsky,
170. Robins-Browne, R.M. & Prpic, J.K. (1983) Desferrioxamine and systemic yersiniosis. Lancet, 2, 1372.
171. Robins-Browne, R.M, Prpic, J.K., & Stuart, S.J. (1987) Yersiniae and iron. A study in host-parasite relationships. Contrib. Microbiol. Immunol., 9, 254-258.
172. Robins-Browne, R.M., Rabson, A.R., & Koornhof, H.J. (1979) Generalized infection with Yersinia enterocolitica and the role of iron. Contrib. Microbiol. Immunol., 5, 277-282.
173. Rodda, C.P., Reid, E.D., Johnson, S., Doery, J., Matthews, R., & Bowden, D.K. (1995) Short stature in homozygous beta-thalassaemia is due to disproportionate truncal shortening. Clin. Endocrinol. (Oxf), 42, 587-592.
174. Roeser, H.P., Halliday, J.W., Sizemore, D.J., Nikles, A., & Willgoss, D. (1980) Serum ferritin in ascorbic acid deficiency. Br. J. Haematol., 45, 459-466.
175. Rubinstein, M., Dupont, P., Doppee, J.P., Dehon, C., Ducobu, J., & Hainaut, J. (1985) Ocular toxicity of desferrioxamine. Lancet, 1, 817-818.
176. Sabato, A.R., De, S., V, Atti, G., Capra, L., Bagni, B., & Vullo, C. (1983) Primary hypothyroidism and the low T3 syndrome in thalassaemia major. Arch. Dis. Child, 58, 120-127.
177. Saenger, P., Schwartz, E., Markenson, A.L., Graziano, J.H., Levine, L.S., New, M.I., & Hilgartner, M.W. (1980) Depressed serum somatomedin activity in beta-thalassemia. J. Pediatr., 96, 214-218.
178. Saito, K., Nishisato, T., Grasso, J.A., & Aisen, P. (1986) Interaction of transferrin with iron-loaded rat peritoneal macrophages. Br. J. Haematol., 62, 275-286.
179. Sands, J.M., Macher, A.M., Ley, T.J., & Nienhuis, A.W. (1985) Disseminated infection caused by Cunninghamella bertholletiae in a patient with beta-thalassemia. Case report and review of the literature. Ann. Intern. Med., 102, 59-63.
180. Schafer, A.I., Rabinowe, S., Le Boff, M.S., Bridges, K., Cheron, R.G., & Dluhy, R. (1985) Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. Arch. Intern. Med., 145, 1217-1221.
181. Sephton Smith, R. (1962) Iron excretion in thalassaemia after administration of chelating agents. Br. Med. J. 2, 1577-1580.
182. Sephton Smith, R. (1964) Chelating agents in the diagnosis and treatment of iron overload in thalassemia. Ann. N.Y. Acad. Sci. 119, 776-788.
183. Shehadeh, N., Hazani, A., Rudolf, M.C., Peleg, I., Benderly, A., & Hochberg, Z. (1990) Neurosecretory dysfunction of growth hormone secretion in thalassemia major. Acta Paediatr. Scand., 79, 790-795.
184. Shirane, M. & Harrison, R.V. (1987) The effects of deferoxamine mesylate and hypoxia on the cochlea. Acta Otolaryngol., 104, 99-107.
185. Simon, P., Ang, K.S., Meyrier, A., Allain, P., & Mauras, Y. (1983) Desferrioxamine, ocular toxicity, and trace metals. Lancet, 2, 512-513.
186. Singh, S., Hider, R.C., & Porter, J.B. (1990) Separation and identification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and fast atom bombardment mass spectrometry: choice of complexing agent and application to biological fluids. Anal. Biochem., 187, 212-219.
187. Sklar, C.A., Lew, L.Q., Yoon, D.J., & David, R. (1987) Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion. Am. J. Dis. Child, 141, 327-330.
188. Solomon, L.R., Hillman, R.S., & Finch, C.A. (1981) Serum ferritin in refractory anemias. Acta Haematol., 66, 1-5.
189. Stefanini, S., Chiancone, E., Cavallo, S., Saez, V., Hall, A.D., & Hider, R.C. (1991) The interaction of hydroxypyridinones with human serum transferrin and ovotransferrin. J. Inorg. Biochem., 44, 27-37.
190. Tamary, H., Goshen, J., Carmi, D., Yaniv, I., Kaplinsky, C., Cohen, I.J., & Zaizov, R. (1994) Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients. Isr. J. Med. Sci., 30, 658-664.
191. Thalassemia International Federation. (2000) Guidelines for the clinical management of thalassemia.
192. Tolis, G., Politis, C., Kontopoulou, I., Poulatzas, N., Rigas, G., Saridakis, C., Athanasiou, V., Mortoglou, A., Malachtari, S., & Ling, N. (1987) Pituitary somatotropic and corticotropic function in patients with beta-thalassemia on iron chelation therapy. Birth Defects Orig. Artic. Ser., 23, 449-452.
193. Villeneuve, J.P., Bilodeau, M., Lepage, R., Cote, J., & Lefebvre, M. (1996) Variability in hepatic iron concentration measurement from needle-biopsy specimens. J. Hepatol., 25, 172-177.
194. Walker, J.A., Sherman, R.A., & Eisinger, R.P. (1985) Thrombocytopenia associated with intravenous desferrioxamine. Am. J. Kidney Dis., 6, 254-256.
195. Wang, C., Tso, S.C., & Todd, D. (1989) Hypogonadotropic hypogonadism in severe beta-thalassemia: effect of chelation and pulsatile gonadotropin-releasing hormone therapy. J. Clin. Endocrinol. Metab, 68, 511-516.
196. Wapnick, A.A., Lynch, S.R., Charlton, R.W., Seftel, H.C., & Bothwell, T.H. (1969) The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion. Br. J. Haematol., 17, 563-568.
197. Waxman, H.S. & Brown, E.B. (1969) Clinical usefulness of iron chelating agents. Prog. Hematol., 6, 338-373.
198. Werther, G.A., Matthews, R.N., Burger, H.G., & Herington, A.C. (1981) Lack of response of nonsuppressible insulin-like activity to short term administration of human growth hormone in thalassemia major. J. Clin. Endocrinol. Metab, 53, 806-809.
199. White, G.P., Bailey-Wood, R., & Jacobs, A. (1976) The effect of chelating agents on cellular iron metabolism. Clin. Sci. Mol. Med., 50, 145-152.
200. Wolfe, L., Olivieri, N., Sallan, D., Colan, S., Rose, V., Propper, R., Freedman, M.H., & Nathan, D.G. (1985) Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N. Engl. J. Med., 312, 1600-1603.
201. Wonke, B., Hoffbrand, A.V., Aldouri, M., Wickens, D., Flynn, D., Stearns, M., & Warner, P. (1989) Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA. Arch. Dis. Child, 64, 77-82.
202. Worwood, M. (1986) Serum ferritin. Clin. Sci. (Colch.), 70, 215-220.
203. Zahner, H. (1992) Microorganisms as producers of Fe(III)-transport compounds. In Gross, K., Aumiller, J., Gelzer, J. (eds) Desferrioxamine ®Desferal: History, Clinical Value, Perspectives. Munich, MMV Medizin Verlag, 11-25.
204. Zurlo, M.G., De Stefano, P., Borgna-Pignatti, C., Di Palma, A., Piga, A., Melevendi, C., Di Gregorio, F., Burattini, M.G., & Terzoli, S. (1989) Survival and causes of death in thalassaemia major. Lancet, 2, 27-30. 125